258 related articles for article (PubMed ID: 25525394)
1. New molecular targets against cervical cancer.
Duenas-Gonzalez A; Serrano-Olvera A; Cetina L; Coronel J
Int J Womens Health; 2014; 6():1023-31. PubMed ID: 25525394
[TBL] [Abstract][Full Text] [Related]
2. Emerging drugs for the treatment of cervical cancer.
Serrano-Olvera A; Cetina L; Coronel J; Dueñas-González A
Expert Opin Emerg Drugs; 2015 Jun; 20(2):165-82. PubMed ID: 25578210
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of current and emerging treatments for cervical cancer.
Duenas-Gonzalez A; Gonzalez-Fierro A
Expert Opin Drug Metab Toxicol; 2019 Aug; 15(8):671-682. PubMed ID: 31340683
[No Abstract] [Full Text] [Related]
4. New pharmacotherapy options for cervical cancer.
Dueñas-Gonzalez A; Cetina L; Coronel J; Cano C; Dolores R
Expert Opin Pharmacother; 2014 Jan; 15(1):51-60. PubMed ID: 24206031
[TBL] [Abstract][Full Text] [Related]
5. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review.
Boussios S; Seraj E; Zarkavelis G; Petrakis D; Kollas A; Kafantari A; Assi A; Tatsi K; Pavlidis N; Pentheroudakis G
Crit Rev Oncol Hematol; 2016 Dec; 108():164-174. PubMed ID: 27931835
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic and targeted systemic therapy in advanced and recurrent cervical cancer: experience from clinical trials.
Seol HJ; Ulak R; Ki KD; Lee JM
Tohoku J Exp Med; 2014 Apr; 232(4):269-76. PubMed ID: 24695215
[TBL] [Abstract][Full Text] [Related]
7. The safety of drug treatments for cervical cancer.
Dueñas-González A; Cetina L; Coronel J; González-Fierro A
Expert Opin Drug Saf; 2016; 15(2):169-80. PubMed ID: 26650333
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF; Farinas-Madrid L; Oaknin A
Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
[TBL] [Abstract][Full Text] [Related]
9. Anticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancer.
Tan S; de Vries EG; van der Zee AG; de Jong S
Curr Cancer Drug Targets; 2012 Feb; 12(2):170-84. PubMed ID: 22165971
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
Reboul FL
Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
[TBL] [Abstract][Full Text] [Related]
11. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin.
Putral LN; Bywater MJ; Gu W; Saunders NA; Gabrielli BG; Leggatt GR; McMillan NA
Mol Pharmacol; 2005 Nov; 68(5):1311-9. PubMed ID: 16120770
[TBL] [Abstract][Full Text] [Related]
12. Targeted Agents in Cervical Cancer: Beyond Bevacizumab.
Marquina G; Manzano A; Casado A
Curr Oncol Rep; 2018 Apr; 20(5):40. PubMed ID: 29611060
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy options for locally advanced and advanced cervical cancer.
Dueñas-González A; Cetina L; Coronel J; Martínez-Baños D
Drugs; 2010 Mar; 70(4):403-32. PubMed ID: 20205484
[TBL] [Abstract][Full Text] [Related]
14. Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.
Krill LS; Tewari KS
Expert Opin Pharmacother; 2015 Apr; 16(5):675-83. PubMed ID: 25643984
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer.
Fury MG; Lee NY; Sherman E; Lisa D; Kelly K; Lipson B; Carlson D; Stambuk H; Haque S; Shen R; Kraus D; Shah J; Pfister DG
Cancer; 2012 Oct; 118(20):5008-14. PubMed ID: 22415650
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapy for cervical carcinoma - current status.
Serkies K; Jassem J
Chin J Cancer Res; 2018 Apr; 30(2):209-221. PubMed ID: 29861606
[TBL] [Abstract][Full Text] [Related]
17. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma.
Schefter T; Winter K; Kwon JS; Stuhr K; Balaraj K; Yaremko BP; Small W; Sause W; Gaffney D;
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):101-5. PubMed ID: 24331655
[TBL] [Abstract][Full Text] [Related]
18. New developments in systemic therapy for advanced biliary tract cancer.
Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
[TBL] [Abstract][Full Text] [Related]
19. Chemoradiotherapy: the new standard care for invasive cervical cancer.
Rose PG
Drugs; 2000 Dec; 60(6):1239-44. PubMed ID: 11152009
[TBL] [Abstract][Full Text] [Related]
20. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
